AU2015356721B2 - CD38 inhibitors and methods of treatment - Google Patents

CD38 inhibitors and methods of treatment Download PDF

Info

Publication number
AU2015356721B2
AU2015356721B2 AU2015356721A AU2015356721A AU2015356721B2 AU 2015356721 B2 AU2015356721 B2 AU 2015356721B2 AU 2015356721 A AU2015356721 A AU 2015356721A AU 2015356721 A AU2015356721 A AU 2015356721A AU 2015356721 B2 AU2015356721 B2 AU 2015356721B2
Authority
AU
Australia
Prior art keywords
mmol
reaction
indole
cyclohexyl
lcms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015356721A
Other languages
English (en)
Other versions
AU2015356721A1 (en
Inventor
J. David BECHERER
Rodolfo Cadilla
David Norman Deaton
Curt Haffner
Brad Richard Henke
Frank PREUGSCHAT
Christie SCHULTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of AU2015356721A1 publication Critical patent/AU2015356721A1/en
Application granted granted Critical
Publication of AU2015356721B2 publication Critical patent/AU2015356721B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015356721A 2014-12-03 2015-11-19 CD38 inhibitors and methods of treatment Ceased AU2015356721B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
US62/086,844 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (2)

Publication Number Publication Date
AU2015356721A1 AU2015356721A1 (en) 2017-06-08
AU2015356721B2 true AU2015356721B2 (en) 2018-03-15

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015356721A Ceased AU2015356721B2 (en) 2014-12-03 2015-11-19 CD38 inhibitors and methods of treatment

Country Status (11)

Country Link
US (1) US9840496B2 (enExample)
EP (1) EP3227275B1 (enExample)
JP (1) JP6550132B2 (enExample)
KR (1) KR20170090478A (enExample)
CN (1) CN107428733A (enExample)
AU (1) AU2015356721B2 (enExample)
BR (1) BR112017011642A2 (enExample)
CA (1) CA2969178A1 (enExample)
ES (1) ES2717260T3 (enExample)
RU (1) RU2017121002A (enExample)
WO (1) WO2016087975A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11337975B2 (en) * 2016-11-23 2022-05-24 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof
SG11202106963YA (en) 2019-01-11 2021-07-29 Omeros Corp Methods and compositions for treating cancer
KR20220061958A (ko) * 2019-07-31 2022-05-13 리본 테라퓨틱스 인코포레이티드 Cd38의 억제제로서의 헤테로바이사이클릭 아미드
WO2021087087A1 (en) 2019-10-30 2021-05-06 Mitobridge Inc. N-cyclohexyl-5-(thiazol-5-yl)-1h-indole-7-carboxamide derivatives and related compounds as cd38 inhibitors for increasing nad+ and for the treatment of e.g. muscular disorders
KR20230051425A (ko) * 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제
CA3195121A1 (en) * 2020-10-09 2022-04-14 Robert A. Volkmann Heteroaryl amide inhibitors of cd38
RS67253B1 (sr) 2021-01-29 2025-10-31 Boehringer Ingelheim Int Azahinolini kao inhibitori cd38
TW202309007A (zh) * 2021-04-30 2023-03-01 大陸商南京艾美斐生物醫藥科技有限公司 化合物及其作為ｃｄ３８抑制劑的用途
TW202310835A (zh) * 2021-07-12 2023-03-16 美商胞質動力學公司 Ｃｄ３８調節劑及其使用方法
WO2024254396A1 (en) * 2023-06-07 2024-12-12 Flagship Pioneering Innovations, Vi, Llc Condensed azines as inhibitors of cyclic adp ribose hydrolase
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101198A1 (en) * 2002-05-30 2003-12-11 Albert Einstein College Of Medicine Of Zeshiva University Improved inhibitors of adp-ribosyl transferases, cyclases, and hydrolases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433840C (en) * 2001-01-04 2010-05-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
US8283368B2 (en) * 2008-08-29 2012-10-09 The Regents Of The University Of Michigan Selective ligands for the dopamine 3 (D3) receptor and methods of using the same
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101198A1 (en) * 2002-05-30 2003-12-11 Albert Einstein College Of Medicine Of Zeshiva University Improved inhibitors of adp-ribosyl transferases, cyclases, and hydrolases

Also Published As

Publication number Publication date
US20170260164A1 (en) 2017-09-14
WO2016087975A1 (en) 2016-06-09
ES2717260T3 (es) 2019-06-20
RU2017121002A3 (enExample) 2019-03-15
BR112017011642A2 (pt) 2018-03-06
EP3227275B1 (en) 2019-01-02
KR20170090478A (ko) 2017-08-07
CN107428733A (zh) 2017-12-01
JP6550132B2 (ja) 2019-07-24
RU2017121002A (ru) 2019-01-11
JP2018501215A (ja) 2018-01-18
US9840496B2 (en) 2017-12-12
CA2969178A1 (en) 2016-06-09
EP3227275A1 (en) 2017-10-11
AU2015356721A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
AU2015356721B2 (en) CD38 inhibitors and methods of treatment
EP3027600B1 (en) 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
US10259816B2 (en) Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
JP6082011B2 (ja) キナーゼ活性のモジュレーターとして使用するためのアミノピリミジン誘導体
EP3790867B1 (en) Kdm1a inhibitors for the treatment of disease
EA029644B1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
UA80184C2 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
UA125631C2 (uk) Нові модулятори 5-гідрокситриптамінового рецептора 7 і спосіб їх застосування
AU2014368368A1 (en) Piperazine derivatives having multimodal activity against pain
CN109890824B (zh) 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
CN105037371A (zh) 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
KR20190026917A (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
EP3008065A1 (en) 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
EP2029537B1 (en) Bicyclic tetrahydropyrrole compounds
WO2018021977A1 (en) Glycine metabolism modulators and uses thereof
US20100311752A1 (en) Substituted pyridazine derivatives
Mésangeau et al. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio) benzo [b] thiophenes as selective MT2 receptor ligands
EP3122735A1 (en) 3-phenyl-7-hydroxy-isocoumarins as macrophage migration inhibitory factor (mif) inhibitors
JP2020505401A (ja) イミダゾピリダジン化合物
CN118359542A (zh) 一种多取代的吡唑类化合物及其制备方法和用途
NZ745305A (en) Novel condensed pyrimidine compound or salt thereof
HK1149554B (en) Substituted pyridazine derivatives which have histamine h3 antagonist activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired